Article Text

PDF
Cardiovascular highlights from non-cardiology journals
  1. Alistair C Lindsay, Editor

Statistics from Altmetric.com

General cardiology

Varenicline: no link with cardiovascular events found in meta-analysis

Varenicline (Champix) is a partial agonist to nicotine receptors, and is approved for smoking cessation therapy. However, the FDA has raised concern about a possible increase in the incidence of cardiovascular events of patients taking the drug in randomised trials. In this meta-analysis, Prochaska et al looked at 22 randomised controlled trials of current tobacco users and compared cardiovascular events in those given varenicline compared to those given placebo. Cardiovascular adverse events were defined if they occurred during drug treatment or within 30 days of discontinuation. All the trials included in the analysis were double blind and placebo controlled, and two included participants with active cardiovascular disease, while eleven enrolled patients with a history of cardiovascular disease. Rates of cardiovascular serious adverse events were 0.63% in the varenicline groups and 0.47% in the placebo groups. The summary estimate for the risk difference (0.27%, p=0.15) was not significant either clinically or statistically.

Conclusions

In this meta-analysis, the use of verenicline was not associated …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.